Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers

By Craig Clough · February 24, 2023, 10:53 PM EST

AbbVie and Teva Pharmaceuticals pushed back Thursday after buyers of the cholesterol drug Niaspan asked the Third Circuit to consider one of its 2022 opinions before deciding whether to deny them...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In Re: Niaspan Antitrust Litigation

Case Number

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

October 14, 2021

Recent Articles By Craig

November 19, 2024
Yoga Teacher Gets 7½ Years For Defrauding Mentally Ill Doctor
November 18, 2024
'Sub-Par' Work By Data Breach Class Attys Earns Lower Fee
November 13, 2024
7th Circ. Won't Halt Ind. Gender-Affirming Care For Minors Ban
October 29, 2024
NY Judge Tosses $14B Decongestant MDL
October 08, 2024
CooperSurgical Fails To Escape Embryo Solution Recall Suits
August 30, 2024
Doctor In Matthew Perry's Death Makes 1st Court Appearance
August 16, 2024
Baltimore Inks $152.5M Opioid Deal With Cardinal Health
July 08, 2024
Patient Says Health System Shares Data With Meta, Google
May 31, 2024
9th Circ. Affirms Toss Of Health Center's $8M Cigna Row
May 23, 2024
Charges Tossed For Army Doc, Wife In Russia Data Leak Case